Just out on The Oncologist our latest study on the prognostic impact of baseline tumor size (BTS) in cancer pts, led by Eleonora Nicolò. BTS showed relevant prognostic value in pts receiving experimental targeted therapies, but only when biomarker-matched. academic.oup.com/oncolo/advance…

In a large (≃1000) RW cohort from Dana-Farber, consistently with prior reports, we found that nearly 30% of breast tumors changed HER2 status after neoadjuvant treatment. This only impacted prognosis if HER2+➡️ HER2-neg. Our latest article now out on EJC. ejcancer.com/article/S0959-…

Long awaited post monarch. Abema post mostly palbo improved PFS with small median but sign HR. Impact prob less in visceral Mets. In ET sensitive without targ mut and with non visceral disease a new option. #ASCO24 OncoAlert Kevin Kalinsky, MD, MS, FASCO

国立がん研究センター中央病院では腫瘍内科の魅力をお伝えするため、「若手医師のための腫瘍内科ステップアップセミナー」を開催します！！ 日時:8月25日（日）13:00-17:00 場所:研究棟＋WEBのハイブリッド ★お申し込みはこちらから★ docs.google.com/forms/d/e/1FAI…

📌 A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases 🧠 annalsofoncology.org/article/S0923-… OncoAlert #OncoAlertAF 👉🏻 T-DXd demonstrated meaningful intracranial efficacy and clinical benefit in OS, with an

☢️ Systematic review and meta-analysis of SABR in oligoprogression published in @RadiotherapyOn1 authors.elsevier.com/c/1jkuTcA0-IX1E Joelle @drdavidpalma Aisling Barry Jacques Raphael

🚨 Final results of the PANTHER trial in high-risk early-stage #BreastCancer: 🧪Dose-dense adjuvant chemotherapy (tDD) vs. standard: 📉Breast Cancer Recurrence-Free Survival (RFS): Significant improvement (HR 0.80; 95% CI: 0.65-0.98; P=0.030). 📉Event-Free Survival (EFS):

#SABCS24 Day 1 Highlights #CommunityOnc: 1. FDA Oncology Reviews recent approvals: #Ribociclib & #Inavolisib 2. #PADMA: HR+ ET + CDK4/6i vs Chemo 1L 3. #DB06: HR+ TDXd 4. #KN522: biomarker analysis SABCS AACR #bcsm #OncTwitter 1/5

Final #SOLO3 results: Olaparib improved ORR & PFS vs nonplatinum chemo in BRCA-mut PSR ovarian ca, but no OS benefit (HR 1.07; p=0.71). Better OS with 2 prior lines (HR 0.83), worse with ≥3 (HR 1.33). BRCA reversion mutations may explain. #PARPi OncoAlert OncoDaily

Results from the VIKTORIA-1 phase 3 trial (2L fulv/palbo/geda vs fulv/geda vs fulv) to be disclosed next Monday morningstar.com/news/globe-new…

Our RCT evaluating whether ePRO monitoring can support pts on T-DXd has just been published! 📈 Better role, cognitive & social functioning 💤 Less fatigue ⚖️ No survival difference, but QOL decline prevented jamanetwork.com/journals/jaman…

A comprehensive overview of Breast Cancer epidemiology and management from India: lessons and learnings. Read the full article. brnw.ch/21wVT6f #bcsm #BreastCancer

ALASCCA試験はNEJM PI3Kパスウェイに異常のある大腸がんをアスピリンで再発予防 ゲノムベースの精密治療から精密予防の時代へ nejm.org/doi/10.1056/NE…

New study: Adjuvant capecitabine in patients with #TripleNegativeBreastCancer after neoadjuvant chemotherapy. 🔓pubmed.ncbi.nlm.nih.gov/40882247/ Mathew Cherian Paolo Tarantino Dr. E Mittendorf Tari King MD Debu Tripathy, MD Sara Tolaney Nabihah Tayob Nancy Lin, MD Daniel Stover, MD, FASCO #AnaGarridoCastro #TNBC

Barriers to #BreastCancer Care for Women Presenting at District and Regional-Level Hospitals in Ghana: Findings From the African Breast Cancer-Disparities in Outcomes Ghana Study. Read the full article: brnw.ch/21wXocE #bcsm

Interesting data for sure and congrats on a great paper - but impossible to assess the contribution of components so would be cautious taking this to the clinic. OncoAlert

📢 Exciting news in #GynOnc! 🇯🇵 Risovalisib (PI3Kα inhibitor) is now approved in Japan for PIK3CA-mt Ovarian Clear Cell Carcinoma. While it's a vital new #PrecisionMedicine option, management of its unique side effects will be essential! #OvarianCancer kk.haihepharma.com/news/news_2026…

How I think about 1st line HER2+ Metastatic Breast Cancer. Decision 1: THP versus T-DXd + P Decision 2: Maintenance based on receptor status OncoAlert #bcsm

当科レジデントの今井先生が、研究所の田中庸介先生の指導のもと、尿膜管がんのゲノム解析から発がん機序を検討し、発表されました。 奨励賞の受賞をされました！！ ncc.go.jp/jp/ri/division…

Axillary staging in HR+/HER2− EBC is evolving toward a biology-driven model. Baseline clinical/imaging node+ is sufficient to guide escalation with abemaciclib, per monarchE trial (~8% absolute IDFS benefit). thebreastonline.com/article/S0960-… OncoAlert #BreastCancer #bcsm